Results 81 to 90 of about 117,631 (302)

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression

Cell Reports, 2018
Summary: Janus kinases (JAKs) and their downstream STAT proteins play key roles in cytokine signaling, tissue homeostasis, and cancer development. Using a breast cancer model that conditionally lacks Janus kinase 1, we show here that JAK1 is essential ...
Barbara L. Wehde, Patrick D. Rädler, Hridaya Shrestha, Stevi J. Johnson, Aleata A. Triplett, Kay-Uwe Wagner   +5 more
doaj   +1 more source

Inhibition of type I interferon induction and signalling by mosquito-borne flaviviruses [PDF]

, 2017
The Flavivirus genus (Flaviviridae family) contains a number of important human pathogens, including dengue and Zika viruses, which have the potential to cause severe disease.
Clark, Jordan J., Cumberworth, Stephanie, Donald, Claire L., Kohl, Alain   +3 more
core   +1 more source

Janus kinase inhibitors in autoimmune diseases [PDF]

Annals of the Rheumatic Diseases, 2013
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea, Apostolos, Kontzias, Kunihiro, Yamaoka, Yoshiya, Tanaka, Arian, Laurence   +4 more
openaire   +2 more sources

Differences in SARS‐CoV‐2 antigen persistence in individuals with systemic autoimmune rheumatic diseases compared to the general population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, Accepted Article.
Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M.M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, RECOVER‐Adult   +18 more
wiley   +1 more source

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

, 2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources

T cells, the next big target in axSpA?

Arthritis &Rheumatology, Accepted Article.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells.
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

-escin mitigates neuroinflammation and apoptosis caused by ischemic stroke through the inhibition of the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway

Journal of International Medical Research
Objective This study aimed to investigate the protective effects of β-escin against neuroinflammatory injury and its influence on the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of ...
Duan Yanqin, Liu Shenglan, Zhang Yu, Deng Yu, Du Qing, Zeng Hongliang, Tan Dianbo, Liu Chunhai, Yin yong, Liu Dongliang   +9 more
doaj   +1 more source